Cancer Research Center, Cancer Institute, Tehran University of Medical Sciences, Tehran, 1419733133, Iran.
Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.
BMC Cancer. 2024 Sep 3;24(1):1092. doi: 10.1186/s12885-024-12663-2.
Despite the severe impact of COVID-19 on cancer patients, data on COVID-19 outcomes in cancer patients from low- and middle-income countries is limited. We conducted a large study about the mortality rate of COVID-19 in cancer patients in Iran.
We analyzed data from 1,079 cancer (average age: 58.2 years) and 5,514 non-cancer patients (average age: 57.2 years) who were admitted for COVID-19 in two referral hospitals between March 2019 and August 2021. Patients were followed up until death or 31st August 2021. Multiple logistic regression models estimated the odds ratio (OR) and 95% confidence intervals (CI) of factors associated with ICU admission and intubation. The Cox regression model estimated hazard ratios (HRs) and 95% CI of factors associated with hospital and post-discharge 60-day mortalities.
The cancer patients had higher ICU admission (OR = 1.65, 95% CI: 1.42-1.91; P-value 0.03) and intubation (OR = 3.13, 95% CI = 2.63-3.73, P-value < 0.001) than non-cancer patients. Moreover, hospital mortality was significantly higher in cancer patients than in non-cancer patients (HR = 2.12, 95% CI: 1.89-2.41, P-value < 0.001). HR for the post-discharge mortality was higher in these patients (HR = 2.79, 95% CI: 2.49-3.11, < 0.001). The hospital, comorbidities, low oxygen saturation, being on active treatment, and non-solid tumor were significantly associated with ICU admission (P-value < 0.05) in cancer patients, while only low oxygen saturation was associated with intubation. In addition, we found that old age, females, low oxygen saturation level, active treatment, and having a metastatic tumor were associated with death due to COVID-19 (P-value < 0.05). Only lung cancer patients had a significantly higher risk of death compared to other cancer types (HR = 1.50, 95% CI: 1.06-2.10, P-value = 0.02).
Cancer patients are at a higher risk of ICU admission, intubation, and death due to COVID-19 than non-cancer patients. Therefore, cancer patients who are infected with COVID-19 require intensive care in the hospital and active monitoring after their discharge from the hospital.
尽管 COVID-19 对癌症患者造成了严重影响,但来自中低收入国家的癌症患者 COVID-19 结局数据有限。我们对伊朗癌症患者 COVID-19 的死亡率进行了一项大型研究。
我们分析了 2019 年 3 月至 2021 年 8 月期间两家转诊医院收治的 1079 名癌症(平均年龄:58.2 岁)和 5514 名非癌症(平均年龄:57.2 岁)患者的数据。患者的随访时间截止到死亡或 2021 年 8 月 31 日。多因素逻辑回归模型估计了与 ICU 入院和插管相关的因素的比值比(OR)和 95%置信区间(CI)。Cox 回归模型估计了与住院和出院后 60 天死亡率相关的因素的风险比(HR)和 95%CI。
癌症患者的 ICU 入院率(OR=1.65,95%CI:1.42-1.91;P 值 0.03)和插管率(OR=3.13,95%CI:2.63-3.73,P 值<0.001)均高于非癌症患者。此外,癌症患者的住院死亡率明显高于非癌症患者(HR=2.12,95%CI:1.89-2.41,P 值<0.001)。这些患者的出院后死亡率 HR 更高(HR=2.79,95%CI:2.49-3.11,P 值<0.001)。在癌症患者中,医院、合并症、低氧饱和度、正在接受积极治疗和非实体瘤与 ICU 入院显著相关(P 值<0.05),而仅低氧饱和度与插管相关。此外,我们发现,年龄较大、女性、低氧饱和度水平、积极治疗和转移性肿瘤与 COVID-19 死亡相关(P 值<0.05)。只有肺癌患者的死亡风险明显高于其他癌症类型(HR=1.50,95%CI:1.06-2.10,P 值=0.02)。
与非癌症患者相比,癌症患者因 COVID-19 而 ICU 入院、插管和死亡的风险更高。因此,感染 COVID-19 的癌症患者在住院期间需要重症监护,并在出院后进行积极监测。